MX347978B - Uso de los anticuerpos anti-il-17a y anti-il-17f en el tratamiento de la resistentes a insulina. - Google Patents
Uso de los anticuerpos anti-il-17a y anti-il-17f en el tratamiento de la resistentes a insulina.Info
- Publication number
- MX347978B MX347978B MX2011010273A MX2011010273A MX347978B MX 347978 B MX347978 B MX 347978B MX 2011010273 A MX2011010273 A MX 2011010273A MX 2011010273 A MX2011010273 A MX 2011010273A MX 347978 B MX347978 B MX 347978B
- Authority
- MX
- Mexico
- Prior art keywords
- insulin
- treatment
- resistant disorders
- disorders
- resistant
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 6
- 102000004877 Insulin Human genes 0.000 title abstract 3
- 108090001061 Insulin Proteins 0.000 title abstract 3
- 229940125396 insulin Drugs 0.000 title abstract 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
Abstract
La presente invención se refiere al tratamiento de tratamientos resistentes a insulina. En particular, la invención se refiere al tratamiento de trastornos resistentes a insulina por administración de IL-17, tales como antagonistas de IL-17A y/o IL-17F, tales como anticuerpos anti-IL-17A y/o IL-17F y/o IL-17Rc, o fragmentos de anticuerpos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16567709P | 2009-04-01 | 2009-04-01 | |
PCT/US2010/029280 WO2010114859A1 (en) | 2009-04-01 | 2010-03-30 | Treatment of insulin-resistant disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2011010273A MX2011010273A (es) | 2011-10-17 |
MX347978B true MX347978B (es) | 2017-05-22 |
Family
ID=42229822
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011010273A MX347978B (es) | 2009-04-01 | 2010-03-30 | Uso de los anticuerpos anti-il-17a y anti-il-17f en el tratamiento de la resistentes a insulina. |
Country Status (24)
Country | Link |
---|---|
US (1) | US20100266595A1 (es) |
EP (1) | EP2413967A1 (es) |
JP (1) | JP5795306B2 (es) |
KR (1) | KR101766927B1 (es) |
CN (1) | CN102448493B (es) |
AR (1) | AR075998A1 (es) |
AU (1) | AU2010232692C1 (es) |
BR (1) | BRPI1011535A2 (es) |
CA (1) | CA2752908A1 (es) |
CL (1) | CL2011002416A1 (es) |
CO (1) | CO6410313A2 (es) |
CR (1) | CR20110552A (es) |
EC (1) | ECSP11011429A (es) |
IL (1) | IL214745A0 (es) |
MA (1) | MA33248B1 (es) |
MX (1) | MX347978B (es) |
NZ (1) | NZ595005A (es) |
PE (1) | PE20120628A1 (es) |
RU (1) | RU2537142C2 (es) |
SG (1) | SG174891A1 (es) |
TW (1) | TWI474833B (es) |
UA (1) | UA105384C2 (es) |
WO (1) | WO2010114859A1 (es) |
ZA (1) | ZA201106076B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050118232A1 (en) * | 2002-02-12 | 2005-06-02 | Elvira Pistolesi | N-acyl-phosphatidyl-ethanolamines and/or mixtures of n-acyl-ethanolamines with phosphatidic acids or lysophosphatidic acids |
KR101508086B1 (ko) | 2008-05-05 | 2015-04-07 | 노비뮨 에스 에이 | 항-il-17a/il-17f 교차-반응성 항체 및 그의 사용 방법 |
US8790642B2 (en) | 2008-08-29 | 2014-07-29 | Genentech, Inc. | Cross-reactive and bispecific anti-IL-17A/F antibodies |
WO2012061129A1 (en) | 2010-10-25 | 2012-05-10 | Genentech, Inc | Treatment of gastrointestinal inflammation and psoriasis a |
US9117641B2 (en) | 2012-10-29 | 2015-08-25 | Perkinelmer Health Sciences, Inc. | Direct sample analysis device adapters and methods of using them |
RU2019128331A (ru) * | 2013-02-04 | 2019-12-16 | Санофи | Стабилизированные фармацевтические составы аналогов инсулина и/или производные инсулина |
TWI641381B (zh) * | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
AU2015205624A1 (en) | 2014-01-09 | 2016-07-14 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
AU2017402210B2 (en) * | 2017-03-10 | 2021-08-19 | Suzhou Kanova Biopharmaceutical Co., Ltd. | Monoclonal antibody against both IL-17A and IL-17F and use of the same |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4783469A (en) | 1986-03-07 | 1988-11-08 | Meier Albert H | Method of inhibiting body fat stores |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5266561A (en) | 1988-01-11 | 1993-11-30 | Amylin Pharmaceuticals, Inc. | Treatment of type 2 diabetes mellitus |
JPH03506023A (ja) | 1988-07-20 | 1991-12-26 | ノボ ノルデイスク アクツイエセルスカプ | ポリペプチド |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5514646A (en) | 1989-02-09 | 1996-05-07 | Chance; Ronald E. | Insulin analogs modified at position 29 of the B chain |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
AU641673B2 (en) | 1989-06-29 | 1993-09-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
ES2087997T3 (es) | 1990-01-12 | 1996-08-01 | Cell Genesys Inc | Generacion de anticuerpos xenogenicos. |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
EP0546073B1 (en) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | production and use of transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
EP0586505A1 (en) | 1991-05-14 | 1994-03-16 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
EP0625200B1 (en) | 1992-02-06 | 2005-05-11 | Chiron Corporation | Biosynthetic binding protein for cancer marker |
AU668423B2 (en) | 1992-08-17 | 1996-05-02 | Genentech Inc. | Bispecific immunoadhesins |
JPH08509203A (ja) | 1992-10-15 | 1996-10-01 | ダナ−ファーバー キャンサー インステテュート インコーポレイテッド | TNF−α作用の拮抗剤を用いる肥満関連糖尿病▲II▼型のインスリン耐性の治療 |
US5527307A (en) | 1994-04-01 | 1996-06-18 | Minimed Inc. | Implantable medication infusion pump with discharge side port |
US5569186A (en) | 1994-04-25 | 1996-10-29 | Minimed Inc. | Closed loop infusion pump system with removable glucose sensor |
US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
US5939269A (en) | 1994-12-28 | 1999-08-17 | The Regents Of The University Of California | Antagonists to insulin receptor tyrosine kinase inhibitor |
US5637095A (en) | 1995-01-13 | 1997-06-10 | Minimed Inc. | Medication infusion pump with flexible drive plunger |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
RU2497500C2 (ru) | 1995-07-27 | 2013-11-10 | Джинентех, Инк | Стабильная изотоническая лиофилизированная протеиновая композиция |
EP0766966A3 (en) | 1995-09-08 | 2001-02-28 | Eli Lilly And Company | Method of treating insulin resistance |
DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
NZ314406A (en) | 1996-03-18 | 2000-12-22 | Sankyo Co | Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles |
PT942968E (pt) | 1996-12-03 | 2008-03-27 | Amgen Fremont Inc | Anticorpos totalmente humanos que se ligam ao egfr |
US20020177188A1 (en) * | 1998-05-15 | 2002-11-28 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
US6040292A (en) | 1999-06-04 | 2000-03-21 | Celtrix Pharmaceuticals, Inc. | Methods for treating diabetes |
US6187333B1 (en) | 1999-09-20 | 2001-02-13 | Diabex, Inc. | Method for treating, controlling, and preventing diabetes mellitus |
ATE541930T1 (de) | 1999-12-23 | 2012-02-15 | Genentech Inc | Il-17-homologe polypeptide und ihre therapeutische verwendung |
US20070160576A1 (en) * | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
AT500646A1 (de) * | 2001-10-15 | 2006-02-15 | Genentech Inc | Behandlung und diagnose von insulinbeständigen zuständen |
CA2488441C (en) | 2002-06-03 | 2015-01-27 | Genentech, Inc. | Synthetic antibody phage libraries |
DE602005013805D1 (de) * | 2004-09-21 | 2009-05-20 | Merck Serono Sa Coinsins | Verwendung von il-17f zur behandlung und/oder prävention von neurologischen erkrankungen |
DE602006009834D1 (de) * | 2005-09-01 | 2009-11-26 | Schering Corp | Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung |
US7790163B2 (en) * | 2006-03-10 | 2010-09-07 | Zymogenetics, Inc. | Antibodies that bind both IL-17A and IL-17F and methods of using the same |
US7910703B2 (en) * | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
TW200902064A (en) * | 2007-03-28 | 2009-01-16 | Wyeth Corp | Methods and compositions for modulating IL-17F/IL-17A biological activity |
EP2150564A2 (en) * | 2007-04-27 | 2010-02-10 | ZymoGenetics, Inc. | Antagonists to il-17a, il-17f, and il-23p19 and methods of use |
WO2008133684A1 (en) * | 2007-04-27 | 2008-11-06 | Zymogenetics, Inc. | Antibodies that bind both il-17a and il-17f and methods of using the same |
JP2010534664A (ja) * | 2007-07-23 | 2010-11-11 | セントコア・オーソ・バイオテツク・インコーポレーテツド | Il−17拮抗薬を用いた線維症関連疾患治療の方法及び組成物 |
CA2701494A1 (en) * | 2007-10-02 | 2009-04-09 | Institut National De La Recherche Scientifique | Method of regulating the th17 pathway and its associated metabolic impact |
-
2010
- 2010-03-30 NZ NZ595005A patent/NZ595005A/en not_active IP Right Cessation
- 2010-03-30 SG SG2011068293A patent/SG174891A1/en unknown
- 2010-03-30 AR ARP100101033A patent/AR075998A1/es not_active Application Discontinuation
- 2010-03-30 US US12/749,876 patent/US20100266595A1/en not_active Abandoned
- 2010-03-30 CN CN201080023924.3A patent/CN102448493B/zh active Active
- 2010-03-30 WO PCT/US2010/029280 patent/WO2010114859A1/en active Application Filing
- 2010-03-30 UA UAA201112634A patent/UA105384C2/ru unknown
- 2010-03-30 MX MX2011010273A patent/MX347978B/es active IP Right Grant
- 2010-03-30 MA MA34316A patent/MA33248B1/fr unknown
- 2010-03-30 AU AU2010232692A patent/AU2010232692C1/en not_active Ceased
- 2010-03-30 RU RU2011144122/15A patent/RU2537142C2/ru not_active IP Right Cessation
- 2010-03-30 CA CA2752908A patent/CA2752908A1/en not_active Abandoned
- 2010-03-30 KR KR1020117025865A patent/KR101766927B1/ko active IP Right Grant
- 2010-03-30 TW TW099109698A patent/TWI474833B/zh not_active IP Right Cessation
- 2010-03-30 BR BRPI1011535A patent/BRPI1011535A2/pt not_active IP Right Cessation
- 2010-03-30 EP EP10712243A patent/EP2413967A1/en not_active Withdrawn
- 2010-03-30 JP JP2012503632A patent/JP5795306B2/ja active Active
- 2010-03-30 PE PE2011001691A patent/PE20120628A1/es not_active Application Discontinuation
-
2011
- 2011-08-18 ZA ZA2011/06076A patent/ZA201106076B/en unknown
- 2011-08-18 IL IL214745A patent/IL214745A0/en unknown
- 2011-08-24 CO CO11108185A patent/CO6410313A2/es not_active Application Discontinuation
- 2011-09-30 CL CL2011002416A patent/CL2011002416A1/es unknown
- 2011-10-19 CR CR20110552A patent/CR20110552A/es unknown
- 2011-11-01 EC EC2011011429A patent/ECSP11011429A/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP2413967A1 (en) | 2012-02-08 |
AU2010232692A1 (en) | 2011-09-08 |
JP2012522788A (ja) | 2012-09-27 |
NZ595005A (en) | 2014-04-30 |
CL2011002416A1 (es) | 2012-04-20 |
RU2011144122A (ru) | 2013-05-10 |
CA2752908A1 (en) | 2010-10-07 |
AU2010232692C1 (en) | 2017-06-01 |
WO2010114859A1 (en) | 2010-10-07 |
CR20110552A (es) | 2011-12-07 |
TWI474833B (zh) | 2015-03-01 |
SG174891A1 (en) | 2011-11-28 |
CO6410313A2 (es) | 2012-03-30 |
AR075998A1 (es) | 2011-05-11 |
US20100266595A1 (en) | 2010-10-21 |
CN102448493B (zh) | 2014-04-30 |
JP5795306B2 (ja) | 2015-10-14 |
UA105384C2 (ru) | 2014-05-12 |
KR101766927B1 (ko) | 2017-08-09 |
KR20120005483A (ko) | 2012-01-16 |
CN102448493A (zh) | 2012-05-09 |
MX2011010273A (es) | 2011-10-17 |
PE20120628A1 (es) | 2012-05-26 |
ZA201106076B (en) | 2012-11-28 |
MA33248B1 (fr) | 2012-05-02 |
AU2010232692B2 (en) | 2016-12-01 |
IL214745A0 (en) | 2011-11-30 |
RU2537142C2 (ru) | 2014-12-27 |
BRPI1011535A2 (pt) | 2016-03-29 |
ECSP11011429A (es) | 2011-12-30 |
TW201038284A (en) | 2010-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX347978B (es) | Uso de los anticuerpos anti-il-17a y anti-il-17f en el tratamiento de la resistentes a insulina. | |
EP2493506A4 (en) | IL-17A ANTAGONISTS | |
MX342810B (es) | Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso. | |
MX2010005856A (es) | Anti-cuerpos anti-vegf. | |
TW201129381A (en) | Antibodies against human CSF-1R and uses thereof | |
MX355256B (es) | Anticuerpos anti-il-17a/il-17f de reactividad cruzada y métodos de uso de los mismos. | |
MX2009006471A (es) | Anticuerpo anti especifico de linfopoyetina estromal timica de diseño. | |
MX348013B (es) | Anticuerpos anti il-17f y metodos de uso de los mismos. | |
MX2009003973A (es) | Moleculas de anticuerpo que unen il-17 e il-17f. | |
JO2576B1 (en) | Antibodies | |
MX2009008104A (es) | Hepcidina, antagonistas de hepcidina y metodos de uso. | |
MX2010005682A (es) | Anticuerpos bivalentes, biespecificos. | |
MX2010005888A (es) | Anticuerpos bivalentes biespecificos. | |
MX2010006396A (es) | Anticuerpos bivalentes, biespecificos. | |
UA100874C2 (en) | Bivalent bispecific antibodies | |
MX2010008688A (es) | Anticuerpos anti-receptor de linfopoyetina estromal timica procesados por ingenieria. | |
WO2007025977A3 (en) | Anti-tnf alpha producing lactic acid bacteria for the treatment of chronic enterocolitis | |
SG178886A1 (en) | Humanized anti-cdcp1 antibodies | |
TN2013000292A1 (en) | Antibody molecules which bind il-17a and il-17f | |
EA201101241A1 (ru) | Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3 | |
MX2011010012A (es) | NUEVOS ANTICUERPOS ANTI-A5ß1 Y SUS USOS. | |
PH12015501296A1 (en) | Solution formulations of engineered anti-il-23p19 antibodies | |
UA105073C2 (uk) | Антитіло проти фракталкіну, композиція і спосіб для лікування запальних порушень | |
PH12013502194A1 (en) | Antibodies to egfl7 and methods for their use | |
MX2011011623A (es) | Antagonistas del receptor tipo toll 3. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |